Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label phase 3 study of subcutaneous mezagitamab in adults with chronic primary immune thrombocytopenia
CTR20252823Phase 3Active
- Sponsor
- Takeda
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of mezagitamab in immune thrombocytopenia (ITP), sponsored by Takeda. Started Aug 2025; status: active.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20252823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252823.